Two-step tuberculin skin testing in HIV-infected persons in Uganda

Michelle T. Hecker, John L. Johnson, Christopher C. Whalen, Sam Nyole, Roy D. Mugerwa, Jerrold J. Ellner

Research output: Contribution to journalArticle

Abstract

Identifying persons infected with both human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (MTB) is often difficult because of the reduced sensitivity of tuberculin skin testing in HIV-infected persons. To determine the value of two-step tuberculin skin testing (TTST) as a method of increasing the sensitivity of tuberculin skin testing in HIV-infected persons, a consecutive sample of 58 HIV-infected persons being screened for a TB preventive therapy trial in Uganda with an initial purified protein derivative (PPD) response <5 mm completed two-step tuberculin and candida skin testing. The mean change in PPD size between the two tests, placed a mean of 8 d apart, was +2.1 mm (SD 4.4 mm, range -4 to +16 mm). Seventeen subjects (29%) had a boosted response (PPD1 <5 and PPD2 ≤ 5). In a multiple logistic regression model, boosted responses were independently associated with a CD4 count between 200 and 500 μl-1 (p = 0.02) and a higher body mass index (p = 0.05). TTST may be valuable in identifying MTB infection and in preventing misclassification of boosted responses as skin test conversions in HIV-infected persons, especially persons with CD4 counts between 200 and 500 μl-1 from areas with a high prevalence of MTB infection or from areas with a low prevalence of MTB infection who have other risk factors for MTB infection.

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume155
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Uganda
Tuberculin
Mycobacterium tuberculosis
Mycobacterium Infections
HIV
Skin
CD4 Lymphocyte Count
Logistic Models
Skin Tests
Candida
Proteins
Body Mass Index

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Hecker, M. T., Johnson, J. L., Whalen, C. C., Nyole, S., Mugerwa, R. D., & Ellner, J. J. (1997). Two-step tuberculin skin testing in HIV-infected persons in Uganda. American Journal of Respiratory and Critical Care Medicine, 155(1), 81-86.

Two-step tuberculin skin testing in HIV-infected persons in Uganda. / Hecker, Michelle T.; Johnson, John L.; Whalen, Christopher C.; Nyole, Sam; Mugerwa, Roy D.; Ellner, Jerrold J.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 1, 1997, p. 81-86.

Research output: Contribution to journalArticle

Hecker, MT, Johnson, JL, Whalen, CC, Nyole, S, Mugerwa, RD & Ellner, JJ 1997, 'Two-step tuberculin skin testing in HIV-infected persons in Uganda', American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 1, pp. 81-86.
Hecker MT, Johnson JL, Whalen CC, Nyole S, Mugerwa RD, Ellner JJ. Two-step tuberculin skin testing in HIV-infected persons in Uganda. American Journal of Respiratory and Critical Care Medicine. 1997;155(1):81-86.
Hecker, Michelle T. ; Johnson, John L. ; Whalen, Christopher C. ; Nyole, Sam ; Mugerwa, Roy D. ; Ellner, Jerrold J. / Two-step tuberculin skin testing in HIV-infected persons in Uganda. In: American Journal of Respiratory and Critical Care Medicine. 1997 ; Vol. 155, No. 1. pp. 81-86.
@article{11c29b57f5d142468a8b623111c08104,
title = "Two-step tuberculin skin testing in HIV-infected persons in Uganda",
abstract = "Identifying persons infected with both human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (MTB) is often difficult because of the reduced sensitivity of tuberculin skin testing in HIV-infected persons. To determine the value of two-step tuberculin skin testing (TTST) as a method of increasing the sensitivity of tuberculin skin testing in HIV-infected persons, a consecutive sample of 58 HIV-infected persons being screened for a TB preventive therapy trial in Uganda with an initial purified protein derivative (PPD) response <5 mm completed two-step tuberculin and candida skin testing. The mean change in PPD size between the two tests, placed a mean of 8 d apart, was +2.1 mm (SD 4.4 mm, range -4 to +16 mm). Seventeen subjects (29{\%}) had a boosted response (PPD1 <5 and PPD2 ≤ 5). In a multiple logistic regression model, boosted responses were independently associated with a CD4 count between 200 and 500 μl-1 (p = 0.02) and a higher body mass index (p = 0.05). TTST may be valuable in identifying MTB infection and in preventing misclassification of boosted responses as skin test conversions in HIV-infected persons, especially persons with CD4 counts between 200 and 500 μl-1 from areas with a high prevalence of MTB infection or from areas with a low prevalence of MTB infection who have other risk factors for MTB infection.",
author = "Hecker, {Michelle T.} and Johnson, {John L.} and Whalen, {Christopher C.} and Sam Nyole and Mugerwa, {Roy D.} and Ellner, {Jerrold J.}",
year = "1997",
language = "English (US)",
volume = "155",
pages = "81--86",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Two-step tuberculin skin testing in HIV-infected persons in Uganda

AU - Hecker, Michelle T.

AU - Johnson, John L.

AU - Whalen, Christopher C.

AU - Nyole, Sam

AU - Mugerwa, Roy D.

AU - Ellner, Jerrold J.

PY - 1997

Y1 - 1997

N2 - Identifying persons infected with both human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (MTB) is often difficult because of the reduced sensitivity of tuberculin skin testing in HIV-infected persons. To determine the value of two-step tuberculin skin testing (TTST) as a method of increasing the sensitivity of tuberculin skin testing in HIV-infected persons, a consecutive sample of 58 HIV-infected persons being screened for a TB preventive therapy trial in Uganda with an initial purified protein derivative (PPD) response <5 mm completed two-step tuberculin and candida skin testing. The mean change in PPD size between the two tests, placed a mean of 8 d apart, was +2.1 mm (SD 4.4 mm, range -4 to +16 mm). Seventeen subjects (29%) had a boosted response (PPD1 <5 and PPD2 ≤ 5). In a multiple logistic regression model, boosted responses were independently associated with a CD4 count between 200 and 500 μl-1 (p = 0.02) and a higher body mass index (p = 0.05). TTST may be valuable in identifying MTB infection and in preventing misclassification of boosted responses as skin test conversions in HIV-infected persons, especially persons with CD4 counts between 200 and 500 μl-1 from areas with a high prevalence of MTB infection or from areas with a low prevalence of MTB infection who have other risk factors for MTB infection.

AB - Identifying persons infected with both human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (MTB) is often difficult because of the reduced sensitivity of tuberculin skin testing in HIV-infected persons. To determine the value of two-step tuberculin skin testing (TTST) as a method of increasing the sensitivity of tuberculin skin testing in HIV-infected persons, a consecutive sample of 58 HIV-infected persons being screened for a TB preventive therapy trial in Uganda with an initial purified protein derivative (PPD) response <5 mm completed two-step tuberculin and candida skin testing. The mean change in PPD size between the two tests, placed a mean of 8 d apart, was +2.1 mm (SD 4.4 mm, range -4 to +16 mm). Seventeen subjects (29%) had a boosted response (PPD1 <5 and PPD2 ≤ 5). In a multiple logistic regression model, boosted responses were independently associated with a CD4 count between 200 and 500 μl-1 (p = 0.02) and a higher body mass index (p = 0.05). TTST may be valuable in identifying MTB infection and in preventing misclassification of boosted responses as skin test conversions in HIV-infected persons, especially persons with CD4 counts between 200 and 500 μl-1 from areas with a high prevalence of MTB infection or from areas with a low prevalence of MTB infection who have other risk factors for MTB infection.

UR - http://www.scopus.com/inward/record.url?scp=0031028315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031028315&partnerID=8YFLogxK

M3 - Article

C2 - 9001293

AN - SCOPUS:0031028315

VL - 155

SP - 81

EP - 86

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -